Precision Medicine International
Founded in 2012, Precision Medicine International is a health IT company dedicated to integrating medical genomics into everyday clinical and lifestyle decision-making.
Our flagship clinical decision support software, the XY Leap™ Omics Platform, delivers over 1,000 evidence-based, DNA-guided precision therapeutics at the point of care — supporting all medical and surgical subspecialties for every patient.
In addition, in 2026 we will launch our innovative Longevity Omics AI Agent to assist healthcare professionals and patients to integrate the advanced preventive medical technology into their daily lives.
By combining genetic testing, biomarker analysis, and advanced data insights, XY Leap™ provides individuals and healthcare providers with a personalized roadmap to optimize health, performance, and longevity.
Private & Public Healthcare
The XY Leap™ Omics Platform delivers safer healthcare through DNA-guided medicines and personalized lifestyle insights—integrating nutrition, exercise, sleep, and environmental factors. Surgical safety and recovery are improved with individualized nutrition and activity prescriptions. Across all medical and surgical subspecialties, XY Leap™ provides Precise, Predictive, Preventive, Participatory, and Personalized (P5) solutions for every patient.
Human Performance & Longevity
The XY Leap™ Omics Platform integrates advanced genomic, epigenomic, and biomarker intelligence to enhance human performance and extend healthspan. By identifying individualized drivers of biological aging, the platform enables clinicians to tailor interventions that slow cellular decline and preserve long-term vitality.
Through precision-guided insights into nutrition, exercise physiology, sleep optimization, stress resilience, and environmental toxin sensitivity, XY Leap™ targets the core molecular pathways that influence aging — including chronic inflammation, oxidative stress, mitochondrial efficiency, hormonal balance, and metabolic regulation.
Oil, Gas and Mining Industries
The XY Leap™ Omics Platform delivers enhanced worker safety, productivity, and performance. Personalized DNA-guided therapeutics reduce the risk of injuries and protect workers from exposure to toxic combustible air pollutants, PFAS forever chemicals (in firefighting foam residue), mercury, silica, and coal dust.
Farming and Agrichemical Worker Safety
The XY Leap™ Omics Platform reduces the harm caused by pesticides, herbicides, and nitrate fertilizers that concentrate in ground water supplies and contribute to the high rates of kidney failure, birth defects, neurological disorders (such as Parkinson Disease) and cancers in farmers and agrichemical workers. Toxicogenomic analysis identifies which pharmaceuticals, traditional medicines and foods increase the pathogenicity of environmental chemicals in each individual worker.
Military Medicine
The XY Leap™ Omics Platform optimizes force readiness in the armed services. One test delivers individualized injury prevention, enhanced pharmaceutical safety and effectiveness, personalized nutrition, and optimized physical training. Pharmacogenetic-guided treatments significantly reduce the risk of suicide with patients achieving remission from their mental illness up to 80% faster than standard treatment.
Safer Aviation and Space Travel
The XY Leap™ Omics Platform delivers the world’s safest airlines with medication optimization for air and ground crew including antidepressants and sedative-hypnotics. Individualized anti-inflammation strategies to reduce repetitive strain injuries, and personalized nutraceuticals to protect against exposure to fuels, paints, pesticides, and boost immune systems for space travel.
Meet the Team
-
Dr Andrew Winnington
Founder & Chief Science Officer
Director
Andrew is a family physician with a strong background in biological science. He combines clinical expertise with a deep understanding of evidence-based medicine to deliver comprehensive, patient-centred care. His scientific training underpins his commitment to applying the latest medical research and technology to improve health outcomes for individuals and families.
-
Rodger Thompson
Chief Executive Officer
Director
Rodger has an extensive background in government and sport organizations, having served as both a CEO and senior consultant. He brings significant leadership experience in strategic planning, governance, and organizational development, and has contributed to national policy and program delivery across multiple sectors.
-
Craig Morris
Business Director & Chief Finance Officer
Director
Craig has an extensive background in global banking and finance, with experience spanning multiple sectors, including healthcare. Over his career, he has held senior leadership roles overseeing financial strategy, risk management, and business development across diverse markets. Craig combines deep industry insight with a strong track record in managing complex organizations and driving sustainable growth in highly regulated environments.
-
Dr Jonathan Chen
Advisor
Dual specialist in Intensive Care Medicine and Internal Medicine, with experience spanning preventive, primary, secondary, and tertiary healthcare. He has worked across diverse clinical and leadership settings, combining academic depth with a pragmatic and practical focus on patient-centred outcomes.
-
Dr Maneesh Deva
Advisor
Clinical Lead Innovation, Institute of Innovation and Improvement, Te Whatu Ora Health New Zealand, Waitematā. Honorary Lecturer (Paediatrics), School of Medicine and Health Sciences, University of Auckland. General Paediatrician, Royal Australasian College of Physicians (2014). Medical Advisor Kidshealth.org.nz. Convenor NZ Paediatric Forum.
-
Dr Ben Simpson
Advisor
Consultant Anaesthetist Timaru Hospital, Associate Dean University of Otago Timaru Campus. BASE jumper and mountain lover.
-
Dr Richard Goldsmith
Advisor
FACEM with diverse clinical experience within Australasia; from large tertiary level trauma centres to sole practice in small rural towns. Also, significant prehospital and retrieval experience. Current Head of Unit at regional emergency department in South Australia.
-
“The new version is perfect compared to other pharmacogenomics tests. It was really impressive for all doctors who ordered your trials”
Dr Junichi Taguchi, MD, PhD, Chief Medical Director, Tokyo Midtown Clinic
-
“Amazing... the reports update themselves as new medical research come to light… absolutely incredible with regards to the diversity of information they give me.”
Gabe Rijpma, Former Senior Director of Health at Microsoft Asia